You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameHexestrol
Accession NumberDB07931  (DB08959)
TypeSmall Molecule
GroupsWithdrawn
DescriptionA synthetic estrogen that has been used as a hormonal antineoplastic agent.
Structure
Thumb
Synonyms
4,4'-(1,2-diethylethylene)diphenol
Erythrohexestrol
Hexanoestrol
Hexoestrolum
Meso-3,4-di(p-hydroxyphenyl)-n-hexane
Meso-hexestrol
Mesohexestrol
Synoestrolum
External Identifiers
  • NSC-9894
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EstrifarNot Available
EstronalNot Available
HexoestrolTai Yu
SynestrolBiopharm
SynoestrolNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Hexestrol diphosphate sodium
171399-06-7
Thumb
  • InChI Key: DNCWQZVLWAEATB-YHCLLLHXSA-J
  • Monoisotopic Mass: 518.02241872
  • Average Mass: 518.257
DBSALT001081
Categories
UNII10BI795R7D
CAS number84-16-2
WeightAverage: 270.3661
Monoisotopic: 270.161979948
Chemical FormulaC18H22O2
InChI KeyPBBGSZCBWVPOOL-HDICACEKSA-N
InChI
InChI=1S/C18H22O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h5-12,17-20H,3-4H2,1-2H3/t17-,18+
IUPAC Name
4-[(3R,4S)-4-(4-hydroxyphenyl)hexan-3-yl]phenol
SMILES
[H][C@](CC)(C1=CC=C(O)C=C1)[C@]([H])(CC)C1=CC=C(O)C=C1
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Aldo-keto reductase family 1 member C1ProteinunknownNot AvailableHumanQ04828 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Hexestrol can be decreased when it is combined with 1,10-Phenanthroline.Experimental
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Hexestrol.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Hexestrol.Experimental, Illicit
3,4-DichloroisocoumarinThe serum concentration of Hexestrol can be decreased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Hexestrol can be decreased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.Experimental
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be increased when it is combined with Hexestrol.Experimental, Illicit
5-androstenedioneThe serum concentration of 5-androstenedione can be increased when it is combined with Hexestrol.Experimental, Illicit
AbciximabHexestrol may decrease the anticoagulant activities of Abciximab.Approved
AcenocoumarolHexestrol may decrease the anticoagulant activities of Acenocoumarol.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Hexestrol.Approved
AcitretinThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Acitretin.Approved
AdapaleneThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Adapalene.Approved
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Hexestrol.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Hexestrol.Experimental
AlitretinoinThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Alitretinoin.Approved, Investigational
AlogliptinThe serum concentration of Hexestrol can be decreased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Hexestrol can be decreased when it is combined with Alpha-1-proteinase inhibitor.Approved
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be increased when it is combined with Hexestrol.Experimental
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Hexestrol.Approved
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Hexestrol.Approved
AmobarbitalThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Amobarbital.Approved, Illicit
AmprenavirThe serum concentration of Hexestrol can be decreased when it is combined with Amprenavir.Approved
AnastrozoleThe therapeutic efficacy of Anastrozole can be decreased when used in combination with Hexestrol.Approved, Investigational
AncrodHexestrol may decrease the anticoagulant activities of Ancrod.Investigational
AnecortaveThe serum concentration of Anecortave can be increased when it is combined with Hexestrol.Investigational
Anthrax immune globulin humanHexestrol may increase the thrombogenic activities of Anthrax immune globulin human.Approved
Antithrombin III humanThe serum concentration of Hexestrol can be decreased when it is combined with Antithrombin III human.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Hexestrol.Investigational
ApixabanThe serum concentration of Hexestrol can be decreased when it is combined with Apixaban.Approved
AprepitantThe serum concentration of Hexestrol can be decreased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Hexestrol can be decreased when it is combined with Aprotinin.Approved, Withdrawn
ArdeparinHexestrol may decrease the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanThe serum concentration of Hexestrol can be decreased when it is combined with Argatroban.Approved, Investigational
ArmodafinilThe serum concentration of Hexestrol can be decreased when it is combined with Armodafinil.Approved, Investigational
ArtemetherThe serum concentration of Hexestrol can be decreased when it is combined with Artemether.Approved
AsunaprevirThe serum concentration of Hexestrol can be decreased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Hexestrol can be decreased when it is combined with Atazanavir.Approved, Investigational
BarbexacloneThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Barbexaclone.Experimental
BarbitalThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Barbital.Illicit
BatimastatThe serum concentration of Hexestrol can be decreased when it is combined with Batimastat.Experimental
BecaplerminHexestrol may decrease the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe serum concentration of Beclomethasone can be increased when it is combined with Hexestrol.Investigational
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Hexestrol.Approved, Investigational
BenazeprilThe serum concentration of Hexestrol can be decreased when it is combined with Benazepril.Approved, Investigational
BenzamidineThe serum concentration of Hexestrol can be decreased when it is combined with Benzamidine.Experimental
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Hexestrol.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Hexestrol.Approved, Investigational
BexaroteneThe serum concentration of Hexestrol can be decreased when it is combined with Bexarotene.Approved, Investigational
BexaroteneThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Bexarotene.Approved, Investigational
Bi201335The serum concentration of Hexestrol can be decreased when it is combined with Bi201335.Investigational
BivalirudinThe serum concentration of Hexestrol can be decreased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Hexestrol can be decreased when it is combined with Boceprevir.Approved
BosentanThe serum concentration of Hexestrol can be decreased when it is combined with Bosentan.Approved, Investigational
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Hexestrol.Approved
C1 Esterase Inhibitor (Human)Hexestrol may increase the thrombogenic activities of C1 Esterase Inhibitor (Human).Approved
C1 Esterase Inhibitor (Recombinant)Hexestrol may increase the thrombogenic activities of C1 Esterase Inhibitor (Recombinant).Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Hexestrol.Approved
CandoxatrilThe serum concentration of Hexestrol can be decreased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Hexestrol can be decreased when it is combined with Candoxatrilat.Experimental
CaptoprilThe serum concentration of Hexestrol can be decreased when it is combined with Captopril.Approved
CarbamazepineThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Carbamazepine.Approved, Investigational
CelecoxibCelecoxib may increase the thrombogenic activities of Hexestrol.Approved, Investigational
CertoparinHexestrol may decrease the anticoagulant activities of Certoparin.Approved
Chenodeoxycholic acidThe therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Hexestrol.Approved
CholestyramineThe serum concentration of Hexestrol can be decreased when it is combined with Cholestyramine.Approved
ChymostatinThe serum concentration of Hexestrol can be decreased when it is combined with Chymostatin.Experimental
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Hexestrol.Approved, Investigational
CilastatinThe serum concentration of Hexestrol can be decreased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Hexestrol can be decreased when it is combined with Cilazapril.Approved
Citric AcidHexestrol may decrease the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobazamThe serum concentration of Hexestrol can be decreased when it is combined with Clobazam.Approved, Illicit
ClobetasolThe serum concentration of Clobetasol can be increased when it is combined with Hexestrol.Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Hexestrol.Approved
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Hexestrol.Approved
CobicistatThe serum concentration of Hexestrol can be decreased when it is combined with Cobicistat.Approved
ColesevelamThe serum concentration of Hexestrol can be decreased when it is combined with Colesevelam.Approved
ColestipolThe serum concentration of Hexestrol can be decreased when it is combined with Colestipol.Approved
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Hexestrol.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Hexestrol.Approved, Investigational
Dabigatran etexilateThe serum concentration of Hexestrol can be decreased when it is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Hexestrol can be decreased when it is combined with Dabrafenib.Approved
DalteparinHexestrol may decrease the anticoagulant activities of Dalteparin.Approved
DanaparoidHexestrol may decrease the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarunavirThe serum concentration of Hexestrol can be decreased when it is combined with Darunavir.Approved
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Hexestrol.Investigational
DesirudinHexestrol may decrease the anticoagulant activities of Desirudin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Hexestrol.Approved
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Hexestrol.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Hexestrol.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Hexestrol.Experimental, Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Hexestrol.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Hexestrol.Vet Approved
DextranHexestrol may decrease the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Hexestrol may decrease the anticoagulant activities of Dextran 40.Approved
Dextran 70Hexestrol may decrease the anticoagulant activities of Dextran 70.Approved
Dextran 75Hexestrol may decrease the anticoagulant activities of Dextran 75.Approved
DicoumarolHexestrol may decrease the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Hexestrol.Approved
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Hexestrol.Approved
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Hexestrol.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Hexestrol.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Hexestrol.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Hexestrol.Approved, Investigational
DyphyllineThe serum concentration of Dyphylline can be increased when it is combined with Hexestrol.Approved
EcabetThe serum concentration of Hexestrol can be decreased when it is combined with Ecabet.Approved, Investigational
Edetic AcidHexestrol may decrease the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanThe serum concentration of Hexestrol can be decreased when it is combined with Edoxaban.Approved
ElafinThe serum concentration of Hexestrol can be decreased when it is combined with Elafin.Investigational
ElvitegravirThe serum concentration of Hexestrol can be decreased when it is combined with Elvitegravir.Approved
EnalaprilThe serum concentration of Hexestrol can be decreased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Hexestrol can be decreased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Hexestrol can be decreased when it is combined with Enalkiren.Experimental
EnoxaparinHexestrol may decrease the anticoagulant activities of Enoxaparin.Approved
EquileninThe serum concentration of Equilenin can be increased when it is combined with Hexestrol.Experimental
EquilinThe serum concentration of Equilin can be increased when it is combined with Hexestrol.Approved
Eslicarbazepine acetateThe serum concentration of Hexestrol can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Hexestrol.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be increased when it is combined with Hexestrol.Approved
Ethyl biscoumacetateHexestrol may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the thrombogenic activities of Hexestrol.Approved, Investigational, Vet Approved
EtoricoxibEtoricoxib may increase the thrombogenic activities of Hexestrol.Approved, Investigational
ExemestaneThe therapeutic efficacy of Exemestane can be decreased when used in combination with Hexestrol.Approved, Investigational
ExenatideThe serum concentration of Hexestrol can be decreased when it is combined with Exenatide.Approved, Investigational
FelbamateThe serum concentration of Hexestrol can be decreased when it is combined with Felbamate.Approved
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Hexestrol.Approved
fluasteroneThe serum concentration of fluasterone can be increased when it is combined with Hexestrol.Investigational
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Hexestrol.Approved
FluindioneHexestrol may decrease the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Hexestrol.Approved, Vet Approved
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Hexestrol.Approved, Investigational
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Hexestrol.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Hexestrol.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Hexestrol.Approved, Withdrawn
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Hexestrol.Approved
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Hexestrol.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Hexestrol.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Hexestrol.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Hexestrol.Approved
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Hexestrol.Approved
FondaparinuxHexestrol may decrease the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumHexestrol may decrease the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FormestaneThe serum concentration of Formestane can be increased when it is combined with Hexestrol.Approved, Investigational, Withdrawn
FosamprenavirThe serum concentration of Hexestrol can be decreased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Hexestrol can be decreased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Hexestrol can be decreased when it is combined with Fosinopril.Approved
FosphenytoinThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Fosphenytoin.Approved
GabexateThe serum concentration of Hexestrol can be decreased when it is combined with Gabexate.Investigational
GeldanamycinThe serum concentration of Hexestrol can be decreased when it is combined with Geldanamycin.Experimental
GM6001The serum concentration of Hexestrol can be decreased when it is combined with GM6001.Experimental
GriseofulvinThe metabolism of Hexestrol can be increased when combined with Griseofulvin.Approved, Vet Approved
HE3286The serum concentration of HE3286 can be increased when it is combined with Hexestrol.Investigational
HeparinHexestrol may decrease the anticoagulant activities of Heparin.Approved, Investigational
HexobarbitalThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Hexobarbital.Approved
HirulogThe serum concentration of Hexestrol can be decreased when it is combined with Hirulog.Experimental
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Hexestrol.Approved, Investigational
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Hexestrol.Approved, Vet Approved
idraparinuxThe serum concentration of Hexestrol can be decreased when it is combined with idraparinux.Investigational
ImidaprilThe serum concentration of Hexestrol can be decreased when it is combined with Imidapril.Investigational
IndinavirThe serum concentration of Hexestrol can be decreased when it is combined with Indinavir.Approved
IsoflurophateThe serum concentration of Hexestrol can be decreased when it is combined with Isoflurophate.Approved, Withdrawn
IsotretinoinThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Isotretinoin.Approved
IstaroximeThe serum concentration of Istaroxime can be increased when it is combined with Hexestrol.Investigational
IxazomibThe serum concentration of Hexestrol can be decreased when it is combined with Ixazomib.Approved
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Hexestrol.Approved, Investigational
LenalidomideHexestrol may increase the thrombogenic activities of Lenalidomide.Approved
LepirudinThe serum concentration of Hexestrol can be decreased when it is combined with Lepirudin.Approved
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Hexestrol.Approved
LinagliptinThe serum concentration of Hexestrol can be decreased when it is combined with Linagliptin.Approved
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Hexestrol.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Hexestrol.Approved
LisinoprilThe serum concentration of Hexestrol can be decreased when it is combined with Lisinopril.Approved, Investigational
LopinavirThe serum concentration of Hexestrol can be decreased when it is combined with Lopinavir.Approved
LumacaftorThe serum concentration of Hexestrol can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may increase the thrombogenic activities of Hexestrol.Approved, Investigational
ME-609The serum concentration of ME-609 can be increased when it is combined with Hexestrol.Investigational
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Hexestrol.Approved
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Hexestrol.Vet Approved
MethohexitalThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Methohexital.Approved
MethylphenobarbitalThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Hexestrol.Approved, Vet Approved
MetreleptinThe serum concentration of Hexestrol can be decreased when it is combined with Metreleptin.Approved
MifepristoneThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Mifepristone.Approved, Investigational
ModafinilThe serum concentration of Hexestrol can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Hexestrol can be decreased when it is combined with Moexipril.Approved
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Hexestrol.Approved, Vet Approved
Mycophenolic acidThe serum concentration of Hexestrol can be decreased when it is combined with Mycophenolic acid.Approved
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Hexestrol can be decreased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabumetoneNabumetone may increase the thrombogenic activities of Hexestrol.Approved
NadroparinHexestrol may decrease the anticoagulant activities of Nadroparin.Approved
NafamostatThe serum concentration of Hexestrol can be decreased when it is combined with Nafamostat.Investigational
NafcillinThe metabolism of Hexestrol can be increased when combined with Nafcillin.Approved
NCX 1022The serum concentration of NCX 1022 can be increased when it is combined with Hexestrol.Investigational
NCX 4016The serum concentration of Hexestrol can be decreased when it is combined with NCX 4016.Investigational
NelfinavirThe serum concentration of Hexestrol can be decreased when it is combined with Nelfinavir.Approved
NevirapineThe serum concentration of Hexestrol can be decreased when it is combined with Nevirapine.Approved
NitroaspirinThe serum concentration of Hexestrol can be decreased when it is combined with Nitroaspirin.Investigational
Oleoyl estroneThe serum concentration of Oleoyl estrone can be increased when it is combined with Hexestrol.Investigational
OmapatrilatThe serum concentration of Hexestrol can be decreased when it is combined with Omapatrilat.Investigational
OspemifeneThe risk or severity of adverse effects can be increased when Hexestrol is combined with Ospemifene.Approved
OtamixabanThe serum concentration of Hexestrol can be decreased when it is combined with Otamixaban.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Hexestrol.Approved
OxcarbazepineThe serum concentration of Hexestrol can be decreased when it is combined with Oxcarbazepine.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Hexestrol.Approved, Vet Approved
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Hexestrol.Approved
ParecoxibParecoxib may increase the thrombogenic activities of Hexestrol.Approved
PentobarbitalThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateHexestrol may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe serum concentration of Hexestrol can be decreased when it is combined with Perindopril.Approved
PhenindioneHexestrol may decrease the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Phenobarbital.Approved
PhenprocoumonHexestrol may decrease the anticoagulant activities of Phenprocoumon.Approved
PhenytoinThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Hexestrol can be decreased when it is combined with Phosphoramidon.Experimental
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Hexestrol.Approved, Nutraceutical
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Hexestrol.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Hexestrol.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Hexestrol.Approved, Vet Approved
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Hexestrol.Experimental
PrimidoneThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Hexestrol can be decreased when it is combined with Prinomastat.Investigational
Protein CHexestrol may decrease the anticoagulant activities of Protein C.Approved
Protein S humanHexestrol may decrease the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeHexestrol may decrease the anticoagulant activities of Protocatechualdehyde.Approved
PrucaloprideThe serum concentration of Hexestrol can be decreased when it is combined with Prucalopride.Approved
QuinaprilThe serum concentration of Hexestrol can be decreased when it is combined with Quinapril.Approved, Investigational
RacecadotrilThe serum concentration of Hexestrol can be decreased when it is combined with Racecadotril.Investigational
RamiprilThe serum concentration of Hexestrol can be decreased when it is combined with Ramipril.Approved
RemikirenThe serum concentration of Hexestrol can be decreased when it is combined with Remikiren.Approved
ReviparinHexestrol may decrease the anticoagulant activities of Reviparin.Approved
RifabutinThe serum concentration of Hexestrol can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Hexestrol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Hexestrol can be decreased when it is combined with Rifapentine.Approved
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Hexestrol.Approved
RitonavirThe serum concentration of Hexestrol can be decreased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Hexestrol can be decreased when it is combined with Rivaroxaban.Approved
RofecoxibRofecoxib may increase the thrombogenic activities of Hexestrol.Investigational, Withdrawn
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Hexestrol.Approved, Investigational
SaquinavirThe serum concentration of Hexestrol can be decreased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Hexestrol can be decreased when it is combined with Saxagliptin.Approved
SecobarbitalThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Hexestrol.Approved, Investigational, Vet Approved
SimeprevirThe serum concentration of Hexestrol can be decreased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Hexestrol can be decreased when it is combined with Sitagliptin.Approved, Investigational
Somatropin recombinantThe therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Hexestrol.Approved, Investigational
SpiraprilThe serum concentration of Hexestrol can be decreased when it is combined with Spirapril.Approved
St. John's WortThe therapeutic efficacy of Hexestrol can be decreased when used in combination with St. John's Wort.Nutraceutical
SulodexideHexestrol may decrease the anticoagulant activities of Sulodexide.Approved, Investigational
TelaprevirThe serum concentration of Hexestrol can be decreased when it is combined with Telaprevir.Approved
TemocaprilThe serum concentration of Hexestrol can be decreased when it is combined with Temocapril.Experimental, Investigational
ThalidomideHexestrol may increase the thrombogenic activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Hexestrol.Approved
ThiamylalThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Thiamylal.Approved, Vet Approved
ThiopentalThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Thiopental.Approved, Vet Approved
ThiorphanThe serum concentration of Hexestrol can be decreased when it is combined with Thiorphan.Experimental
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Hexestrol.Approved
TipranavirHexestrol may increase the dermatologic adverse activities of Tipranavir.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Hexestrol.Approved
TopiramateThe serum concentration of Hexestrol can be decreased when it is combined with Topiramate.Approved
TrandolaprilThe serum concentration of Hexestrol can be decreased when it is combined with Trandolapril.Approved
Tranexamic AcidHexestrol may increase the thrombogenic activities of Tranexamic Acid.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Hexestrol.Approved, Investigational
TretinoinThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Hexestrol.Approved, Vet Approved
UbenimexThe serum concentration of Hexestrol can be decreased when it is combined with Ubenimex.Experimental
UlinastatinThe serum concentration of Hexestrol can be decreased when it is combined with Ulinastatin.Investigational
Ursodeoxycholic acidThe therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Hexestrol.Approved, Investigational
ValdecoxibValdecoxib may increase the thrombogenic activities of Hexestrol.Investigational, Withdrawn
VildagliptinThe serum concentration of Hexestrol can be decreased when it is combined with Vildagliptin.Approved, Investigational
Vitamin CThe serum concentration of Hexestrol can be increased when it is combined with Vitamin C.Approved, Nutraceutical
VoriconazoleThe metabolism of Hexestrol can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinHexestrol may decrease the anticoagulant activities of Warfarin.Approved
XimelagatranThe serum concentration of Hexestrol can be decreased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
Ym150The serum concentration of Hexestrol can be decreased when it is combined with Ym150.Investigational
Food InteractionsNot Available
References
Synthesis Reference

U.S. Patent 2,357,985; U.S. Patent 2,421,401.

General References
  1. Liehr JG, Ballatore AM, Dague BB, Ulubelen AA: Carcinogenicity and metabolic activation of hexestrol. Chem Biol Interact. 1985 Oct;55(1-2):157-76. [PubMed:2998630 ]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9959
Blood Brain Barrier+0.7575
Caco-2 permeable+0.8705
P-glycoprotein substrateNon-substrate0.5375
P-glycoprotein inhibitor INon-inhibitor0.8556
P-glycoprotein inhibitor IINon-inhibitor0.8622
Renal organic cation transporterNon-inhibitor0.8652
CYP450 2C9 substrateNon-substrate0.7865
CYP450 2D6 substrateNon-substrate0.8813
CYP450 3A4 substrateNon-substrate0.602
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.7855
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorNon-inhibitor0.5469
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8156
Ames testNon AMES toxic0.9648
CarcinogenicityNon-carcinogens0.6254
BiodegradationNot ready biodegradable0.9528
Rat acute toxicity1.9859 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8238
hERG inhibition (predictor II)Non-inhibitor0.5976
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point185U.S. Patent 2,357,985; U.S. Patent 2,421,401.
Predicted Properties
PropertyValueSource
Water Solubility0.0139 mg/mLALOGPS
logP4.98ALOGPS
logP5.37ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)9.93ChemAxon
pKa (Strongest Basic)-5.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area40.46 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity82.66 m3·mol-1ChemAxon
Polarizability31.31 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassStilbenes
Sub ClassNot Available
Direct ParentStilbenes
Alternative Parents
Substituents
  • Stilbene
  • Phenylpropane
  • Phenol
  • Benzenoid
  • Monocyclic benzene moiety
  • Hydrocarbon derivative
  • Organooxygen compound
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity
Specific Function:
Converts progesterone to its inactive form, 20-alpha-dihydroxyprogesterone (20-alpha-OHP). In the liver and intestine, may have a role in the transport of bile. May have a role in monitoring the intrahepatic bile acid concentration. Has a low bile-binding ability. May play a role in myelin formation.
Gene Name:
AKR1C1
Uniprot ID:
Q04828
Molecular Weight:
36788.02 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Comments
comments powered by Disqus
Drug created on September 15, 2010 15:27 / Updated on August 17, 2016 12:24